p53 nuclear accumulation as an early indicator of lethal prostate cancer.
Br J Cancer
; 121(7): 578-583, 2019 10.
Article
en En
| MEDLINE
| ID: mdl-31409910
ABSTRACT
BACKGROUND:
After radical prostatectomy (RP) for prostate cancer (PC), p53 alterations predict biochemical relapse (BCR), however, recent evidence suggests that metastatic relapse (MR) not BCR is a surrogate for PC specific mortality (PCSM). This updated analysis of a previously published study investigated the association between p53 aberrations, MR and PCSM in men with localised PC.METHODS:
Two hundred and seventy-one men with localised PC treated with RP were included. RP specimens stained for p53 by immunohistochemistry were scored as (a) percentage of p53-positive tumour nuclei; and (b) clustering, where ≥12 p53-positive cells within a ×200 power field was deemed 'cluster positive'. Associations between p53 status and clinical outcomes (BCR, MR and PCSM) were evaluated.RESULTS:
Increasing percentage of p53-positive nuclei was significantly associated with shorter time to BCR, MR and PCSM (All p < 0.001). Half of the patients were p53 cluster positive. p53 cluster positivity was significantly associated with poorer outcomes at all clinical endpoints (BCR HR 2.0, 95% CI 1.51-2.65, p < 0.001; MR HR 4.1, 95% CI 2.02-8.14, p < 0.001; PCSM HR 12.2, 95% CI 1.6-93; p = 0.016). These associations were independent of other established prognostic variables.CONCLUSIONS:
p53 aberrations in radical prostatectomy tissue predict clinically relevant endpoints of MR and PCSM.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Núcleo Celular
/
Proteína p53 Supresora de Tumor
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Cancer
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos